Bausch + Lomb Corp(BLCO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.48 | Insider Own | 88.79% | Shs Outstand | 357.1M | Perf Week | 4.08% |
| Market Cap | 6.29B | Forward P/E | 15.97 | EPS next Y | 38.95% | Insider Trans | -0.02% | Shs Float | 40.0M | Perf Month | 3.95% |
| Enterprise Value | 11.10B | PEG | 0.38 | EPS next Q | 0.21 | Inst Own | 10.12% | Short Float | 6.35% | Perf Quarter | 8.77% |
| Income | -0.17B | P/S | 1.18 | EPS this Y | 55.65% | Inst Trans | -0.45% | Short Ratio | 5.65 | Perf Half Y | 12.09% |
| Sales | 5.32B | P/B | 0.99 | EPS next 5Y | 41.86% | ROA | -1.24% | Short Interest | 2.54M | Perf YTD | 3.16% |
| Book/sh | 17.86 | P/C | 16.65 | EPS past 3/5Y | - | ROE | -2.67% | 52W High | -6.85% ($18.92) | Perf Year | 14.64% |
| Cash/sh | 1.06 | P/FCF | 44.91 | Sales past 3/5Y | 10.62% 8.38% | ROIC | -1.49% | 52W Low | 22.02% ($14.44) | Perf 3Y | 11.66% |
| Dividend Est. | - | EV/EBITDA | 13.6 | EPS Y/Y TTM | 37.7% | Gross Margin | 56.97% | Volatility(W/M) | 2.68% 2.94% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.08 | Sales Y/Y TTM | 8.85% | Oper. Margin | 7.61% | ATR (14) | 0.5 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.02 | EPS Q/Q | 77.64% | Profit Margin | -3.21% | RSI (14) | 60.2 | Recom | 2.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.55 | Sales Q/Q | 9.08% | SMA20 | 3.93% ($16.95) | Beta | 0.56 | Target Price | $19.46 |
| Payout | - | Debt/Eq | 0.8 | Earnings | 2026/10/28 | SMA50 | 2.63% ($17.17) | Rel Volume | 1 | Prev Close | $17.58 |
| Employees | 13000 | LT Debt/Eq | 0.8 | EPS/Sales Surpr. | -2.85% 1.81% | SMA200 | 5.95% ($16.63) | Avg Volume(3M) | 0.45M | Price | $17.62 |
| IPO | 2022/5/6 | Option/Short | Yes/Yes | Trades | 4125 | Volume | 450,806 | Change | 0.23% |
👁️ This U.S. ophthalmic healthcare company offers a broad range of eye health products. It supplies contact lenses and lens care solutions, ophthalmic pharmaceuticals, and cataract and other ophthalmic surgical equipment and consumables, making it a medical device stock whose performance is tied to aging-driven eye care demand and new product cycles. A key feature is its high share of recurring revenue from lenses and consumables.
Over the past 1 year, roughly in the middle
7% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
Next earnings report: October 28
That is today.
BLCO keeps an operating profit but posts a net loss
Of every $100 in sales, $7.61 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +55.6% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $118. Peers typically go for $272.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be +11.7%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 10.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #14 of 51 in the industry
Based on market cap of $6B.
FAQ
What kind of company is BLCO?
BLCO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of BLCO?
The market cap of BLCO is approximately $6.3B, ranking 1,200 within its sector.
What is the 52-week high and low for BLCO?
BLCO has recorded a 52-week high of $18.92 and a low of $14.44.